A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy

Medicine
George PapaxoinisHelen Gogas

Abstract

Immune checkpoint inhibitors (ICIs) represent an important advance in the treatment of melanoma. ICIs may induce autoimmune phenomena caused by concurrent activation of the immune system against normal cells. During the last years, cases of musculoskeletal side effects, especially immune-mediated arthritis (IA), have been increasingly reported. We present a 59-year-old woman, who was treated with pembrolizumab for a relapsed BRAF V600E mutated cutaneous malignant melanoma. The patient presented with right knee arthritis on week 30. The erythrocyte sedimentation rate and serum C-reactive protein levels were elevated, while rheumatoid factor and anti-cyclic citrullinated peptide antibodies were negative. Imaging confirmed the presence of fluid mainly in the suprapatellar bursa. Synovial fluid analysis revealed an inflammatory effusion, while other etiologies of inflammatory arthritis were excluded. Arthritis improved with an intra-articular injection of 8 mg dexamethasone. Twelve days later the arthritis relapsed in both knees, and although it was resistant to nonsteroidal anti-inflammatory treatment, it improved with systemic steroids. Tapering of methylprednisolone dose was feasible with the coadministration of leflunomide and ...Continue Reading

References

Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 17, 2016·Annals of the Rheumatic Diseases·Laura C CappelliClifton O Bingham
Aug 27, 2016·Annals of Translational Medicine·Panagiotis Diamantopoulos, Helen Gogas
Jun 11, 2017·Annals of the Rheumatic Diseases·Rakiba BelkhirXavier Mariette
Sep 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee
Nov 11, 2017·Arthritis Care & Research·Melanie H Smith, Anne R Bass
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Feb 20, 2018·Clinical Rheumatology·Jun InamoTsutomu Takeuchi
May 5, 2018·Annals of the Rheumatic Diseases·Laurent ArnaudJoe-Elie Salem
Oct 5, 2018·Modern Rheumatology·Kei OhnumaChikao Morimoto
Nov 10, 2018·Seminars in Arthritis and Rheumatism·Meghan J MooradianSara R Schoenfeld
Nov 16, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emma L MitchellShahneen Sandhu
Mar 15, 2019·Current Opinion in Rheumatology·Xerxes PundoleMaria E Suarez-Almazor
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.